-
First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials
•
First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. This funding round was led by Guangdong Lianjing Investment Group, marking a significant step forward for the company. The proceeds from this investment will be directed towards the…
-
China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices
•
The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification titled “Key Points for Correcting Unhealthy Practices in the Field of Pharmaceutical Procurement/Sales and Medical Services in 2023”. This notice marks the first work deployment following the adjustment of the “Member units of the Interministerial…
-
Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to €14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to €2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry. Pharmaceuticals Unit…
-
Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE
•
The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products Co., Ltd’s oral hexavalent reconstituted rotavirus live vaccine (Vero cells) is on course for priority review. This priority status is granted for the vaccine’s use in preventing acute gastroenteritis caused by rotavirus in infants and…
-
Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled Phase II clinical study for its drug candidate KX-826 (pyrilutamide) in the US for the treatment of male patients with androgenetic alopecia (AGA). The study demonstrated that KX-826 can promote hair growth, with statistically and…
-
ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development
•
ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with NNIT, a Denmark-headquartered provider of digital life sciences solutions. Under the terms of the agreement, NNIT will support ZhenGe in developing a more reliable digitalization platform that offers full lifecycle digital solutions, from…
-
CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China
•
The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent linkage cases, following the new legal framework introduced with China’s amended Patent Law, which came into effect from July 2021. Decisions on Generic and Originator PatentsThe decisions covered 9 molecules and 19 patent challenge verdicts,…
-
Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA
•
Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a Phase II clinical trial filing for its CKBA ointment in the treatment of vitiligo. The Category 1 chemical drug is also currently undergoing a Phase IIa clinical…
-
Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its clinical trial application for 7MW3711, an antibody drug conjugate (ADC) targeting B7-H3, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of advanced solid tumors.…
-
CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo
•
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for Tibsovo (ivosidenib), a first-in-class IDH1 inhibitor, from the European Committee. This marks a significant expansion in the drug’s approved uses for treating specific types of leukemia and cholangiocarcinoma. New Indications for Tibsovo in EuropeTibsovo is…
-
Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults
•
China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing the higher dose (9mg) of mazdutide (IBI362) in Chinese adults with obesity has achieved its 24-week primary endpoint. This milestone marks a significant step forward in the development of this potential treatment for obesity. Study…
-
Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion
•
The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the healthcare sector, with a significant focus on Basic Medical Insurance (BMI). The initiatives aim to enhance the healthcare system and improve access to medical services for residents. 1. Expansion of Long-Term Care Insurance Pilot ProjectsThe…
-
Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that it has obtained market approval from the National Medical Products Administration (NMPA) for its triptorelin microspheres. This treatment is designed for prostate cancer patients who require androgen castration therapy. Innovative Treatment Option for Prostate Cancer…
-
Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC
•
The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB) repotrectinib is on track to receive priority review status in China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive. This priority review status is a reflection of…
-
Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted for review its Category 1 new drug application (NDA) for A166, an anti-HER2 antibody drug conjugate (ADC). The drug is intended for the treatment of HER2 positive locally…
-
Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with US-based DNA solutions provider Synbio Technologies. The collaboration aims to integrate resources across the cell and gene therapy (CGT) industry chain, thereby strengthening the development of the CGT industry in China. Porton…
-
Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical trial approval in China for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb). The National Medical Products Administration (NMPA) has given the go-ahead for the drug to be assessed as a treatment for advanced…
-
Akeso Biopharma Initiates Phase III Study for Ivonescimab in Non-Small Cell Lung Cancer
•
China-based Akeso Biopharma (HKG: 9926) has announced the initiation of a Phase III clinical study for its bispecific antibody (BsAb) ivonescimab (AK112), which targets both programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC). Global Phase III HARMONi Study Design and Patient DosingThe global,…
-
Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights
•
China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first quarter of 2023, along with recent product highlights and corporate updates. The company reported total product revenues of USD 62.8 million for the quarter, marking a 36% year-on-year (YOY) growth. Product Sales and ContributionsThe…
-
Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval from the National Medical Products Administration (NMPA) for its efbemalenograstim alfa (F-627). This in-house developed long-acting recombinant human granulocyte colony stimulating factor (rhGCSF)-Fc fusion protein is indicated for the prevention and treatment of neutropenia in…
